ClinicalTrials.gg
CompletedNCT06233916Updated Feb 1, 2024

Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

A Phase 1 interventional study of [14C] D-1553 in Mass Balance Study, sponsored by InventisBio Co., Ltd. Completed at 1 site in China. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Jan 2024, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
Male
01

Study summary

  • To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of [14C] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans;
  • To obtain radioactive metabolite profiles of human plasma, urine and feces , identify major metabolites of D-1553 and determine the major metabolic pathways and elimination pathways;
  • To quantitatively analyze the TRA in whole blood and plasma and obtain PK parameters of plasma TRA and investigate whole blood/plasma ratio for TRA.
Read the detailed description

Primary Objectives:

  • To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of [14C] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans;
  • To obtain radioactive metabolite profiles of human plasma, urine and feces after a single oral dose of [14C] D-1553 in healthy subjects, identify major metabolites of D-1553 and determine the major metabolic pathways and elimination pathways;
  • To quantitatively analyze the TRA in whole blood and plasma after a single oral dose of [14C] D-1553 in subjects, and obtain PK parameters of plasma TRA and investigate whole blood/plasma ratio for TRA.

Secondary Objectives:

  • To observe the safety of a single oral dose of [14C] D-1553 in healthy subjects;
  • To quantitatively analyze the concentration of D-1553 and its metabolites (if applicable) in plasma using the validated LC-MS (liquid chromatography-mass spectrometry)/MS method and obtain the pharmacokinetic (PK) parameters of D-1553 and its metabolites (if applicable) in plasma.
02

Conditions studied

  • Mass Balance Study
03

In context

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who volunteer to participate in this clinical trial, understand the study procedures and sign the Form (ICF) in writing.
  • Healthy Chinese adult male subjects aged 19-55 years (inclusive) at the time of signing the ICF.
  • Body weight ≥ 50.0 kg, 19 kg/m2 ≤ (BMI) ≤ 26.0 kg/m2, and BMI = body weight (kg)/body height2 (m2) at screening.
  • Subjects with normal test results or with abnormal but not results as judged by the clinician for vital signs, physical examination, 12-lead , chest radiograph (PA view), abdominal color Doppler ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), ophthalmological examination, and laboratory tests (including hematology, blood chemistry, coagulation function, urinalysis, thyroid function, screening for infectious diseases, stool routine test + occult blood) during screening.
  • Subjects who agree to abstain, are surgically sterilized, or agree to use an effective method from the time of signing the ICF and for the duration of study participation to 180 days after administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Subjects with any medical history of disorders of the central nervous system, cardiovascular system, blood and lymphatic system, immune system, urinary system, digestive system, respiratory system, and metabolic and skeletal system, etc., other acute or chronic diseases or mental diseases, which are abnormal and at the discretion of the investigator.
  • Subjects who are positive for surface antigen (HBsAg), antibody, treponema pallidum antibody (TPA), or antigen/antibody combination test (preliminary screening).
  • Subjects who have smoked more than 5 cigarettes or 1 pipe per day (or equivalent of nicotine products) on average within 3 months prior to screening, or who are unable to stop using any tobacco products during the trial.
  • Subjects with hemorrhoids with hematochezia or perianal disease with regular/ongoing hematochezia, or with severe nausea, vomiting, constipation or diarrhea within one week prior to screening; or with positive test results for fecal occult blood.
  • Subjects with a history of blood or needle phobia.
  • Subjects who have undergone a major surgery that affects the absorption or metabolism of the study drug within 6 months prior to the first dose.
  • Subjects who have participated in clinical trials of other study drugs within 3 months before the first dose; if the half-life of that other drug is long, the time period is limited to 5 half-lives of the drug.
  • Subjects unwilling or unable to follow the life restrictions described in the study protocol (such as dietary restrictions, activity and requirements, etc.).
  • Subjects who have lost blood or donated blood, or received blood transfusions or used blood products within 1 month before administration.
  • Subjects who are exposed to radioactive work conditions for a long time, or have significant radiation exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-ray examinations) within 1 year before the first dose, or have participated in a radiopharmaceutical labeled trial.
  • Subjects who are unsuitable for the study participation for other reasons at the discretion of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Other
    [14C] D-1553 group

    Single arm study

    Drug: [14C] D-1553

Interventions

  • \[14C\] D-1553 (approximately 400 mg/80 μCi)

06

What researchers measure

Primary outcomes

  1. The radioactivity will be determined by a liquid scintillation counter. Analyze the total recovery (that is the ratio of the radioactivity in excrement samples to the radioactivity of the drug that administered ) in excrement

    Recovery and cumulative recovery of total radioactive substance in excrement (urine and feces)

    Time frame: 2 weeks

  2. Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose

    Exposure in plasma; percentage of unchanged drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces

    Time frame: 2 weeks

  3. whole blood/plasma ratio for TRA (total radioactivity) concentration at different time points

    whole blood/plasma ratio for TRA concentration at different time points

    Time frame: 2 weeks

  4. Tmax (time to maximum observed concentration) parameters of TRA;

    Tmax parameters of TRA in plasma

    Time frame: baseline to 2 weeks

  5. t1/2 (terminal elimination half-life) parameters of TRA;

    t1/2 parameters of TRA in plasma

    Time frame: baseline to 2 weeks

  6. Cmax (maximum concentration) parameters of TRA;

    Cmax parameters of TRA in plasma

    Time frame: baseline to 2 weeks

  7. MRT (mean residence time) parameters of TRA;

    MRT parameters of TRA in plasma

    Time frame: baseline to 2 weeks

  8. AUC (area under curve) parameters of TRA;

    AUC parameters of TRA in plasma

    Time frame: baseline to 2 weeks

Secondary outcomes

  1. Incidence and severity of AEs based on NCI CTCAE V5.0

    Incidence and severity of adverse events (AEs) graded based on NCI CTCAE V5.0

    Time frame: baseline to 3 weeks

  2. Incidence and severity of SAEs based on NCI CTCAE V5.0

    Incidence and severity of serious adverse events (SAEs) graded based on NCI CTCAE V5.0

    Time frame: baseline to 3 weeks

  3. Tmax parameters of D-1553 and its metabolites

    Tmax parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  4. Cmax parameters of D-1553 and its metabolites

    Cmax parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  5. AUC0-t parameters of D-1553 and its metabolites

    AUC0-t parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  6. T1/2 parameters of D-1553 and its metabolites

    T1/2 parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  7. MRT parameters of D-1553 and its metabolites

    MRT parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  8. CL/F (apparent clearance) parameters of D-1553 and its metabolites

    CL/F parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

  9. Vz/F (apparent volume of distribution) parameters of D-1553 and its metabolites

    Vz/F parameters of D-1553 and its metabolites (if applicable) in plasma

    Time frame: baseline to 2 weeks

07

Study locations

1 site
  • beijing Gobroad Boren Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Jan 2024, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Jan 31, 2024
StartActual
Dec 8, 2023
Primary completionActual
Jan 3, 2024
CompletionActual
Jan 10, 2024
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06233916
Responsible party
Sponsor
First posted
Jan 31, 2024
Start date
Dec 8, 2023
Primary completion
Jan 3, 2024
Completion
Jan 10, 2024
Last update
Feb 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garsorasib

Start the discussion